Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 6,076 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Hydrolyzed Chicken Collagen Type II in Alleviating Joint Discomfort

NCT04955353
View directory record Official record
Conditions
Joint Discomfort
Interventions
AVC-H2, Placebo
Dietary Supplement
Lead sponsor
Avicenna Nutraceutical
Other
Eligibility
40 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

NCT00570128
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 29, 2026, 6:12 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577
View directory record Official record
Conditions
Prostate Cancer
Interventions
capivasertib, docetaxel, placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Yuma, Arizona • Beverly Hills, California • Cerritos, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

NCT02389881
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-058, TAK-058 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austsitn, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 29, 2026, 6:12 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in IgA Nephropathy

NCT02808429
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, Atacicept 25 mg, Atacicept 75 mg
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Not applicable Interventional

Neuromuscular Control in Individuals Following ACL-Reconstruction

NCT04495075
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Quadriceps Muscle Atrophy
Interventions
Visuomotor Therapy, Passive Motion
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 29, 2026, 6:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Erythropoietin in Myelodysplastic Syndrome

NCT00723112
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

NCT04208412
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900, Placebo
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

NCT04023994
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 29, 2026, 6:12 AM EDT
Recruiting Phase 2 Interventional

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637
View directory record Official record
Conditions
Treatment-resistant Depression (TRD)
Interventions
ALTO-207, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
53
States / cities
Dothan, Alabama • Phoenix, Arizona • Chino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

NCT04709575
View directory record Official record
Conditions
Allergic Rhinitis, Conjunctivitis
Interventions
REGN5713, REGN5714, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Bangor, Maine • Baltimore, Maryland • Plymouth, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 1 Interventional

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

NCT01994473
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo, SEP-363856 Open Label
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

NCT01629966
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Glendale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Interplay Between Deciding and Acting With Mild Cognitive Impairment

NCT06493422
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Reaching Movements
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
45 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
C16TR, Placebo, Tyvaso®
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 2 Interventional

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

NCT07108153
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
SION-719, Placebo-to-match SION-719
Drug
Lead sponsor
Sionna Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

NCT00464737
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 29, 2026, 6:12 AM EDT
Recruiting Phase 2 Interventional

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294, Placebo
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

NCT05362695
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IW-3300, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 29, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

NCT02357901
View directory record Official record
Conditions
Opioid Dependence, Opioid Related Disorders
Interventions
SUBOXONE, RBP-6000, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
38
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 29, 2026, 6:12 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265
View directory record Official record
Conditions
Narcolepsy
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 29, 2026, 6:12 AM EDT